Luca Gianni

Luca Gianni

UNVERIFIED PROFILE

Are you Luca Gianni?   Register this Author

Register author
Luca Gianni

Luca Gianni

Publications by authors named "Luca Gianni"

Are you Luca Gianni?   Register this Author

100Publications

4021Reads

13Profile Views

Evaluation of three advanced methodologies, COLD-PCR, microarray and ddPCR, for identifying the mutational status by liquid biopsies in metastatic colorectal cancer patients.

Clin Chim Acta 2019 Feb 12;489:136-143. Epub 2018 Dec 12.

Unit of Genomic for the Diagnosis of Human Pathologies, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Laboratory of Clinical Molecular Biology, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2018.12.004DOI Listing
February 2019

Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.

Cancer Treat Rev 2019 Jan 29;72:1-6. Epub 2018 Oct 29.

Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372183017
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2018.10.013DOI Listing
January 2019

Is there room for another HER2-targeting drug?

Authors:
Luca Gianni

Lancet Oncol 2018 07 24;19(7):847-849. Epub 2018 May 24.

Department of Medical Oncology, Ospedale San Raffaele-IRCCS, 20132 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30405-4DOI Listing
July 2018

HER2-positive breast cancer.

Lancet 2017 Jun 7;389(10087):2415-2429. Epub 2016 Dec 7.

San Raffaele Hospital Scientific Institute, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(16)32417-5DOI Listing
June 2017

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.

Front Med (Lausanne) 2017 23;4. Epub 2017 Jan 23.

Department of Oncology, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2017.00004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253463PMC
January 2017

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Nat Rev Clin Oncol 2016 Nov 17;13(11):674-690. Epub 2016 May 17.

Department of Medical Oncology, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132 Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.66DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461122PMC
November 2016

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma.

Mol Cancer Ther 2016 04 25;15(4):702-10. Epub 2016 Jan 25.

Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Neurology Clinic & National Center for Tumor Diseases, Ruprecht-Karls University, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0582DOI Listing
April 2016

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Breast Cancer Res Treat 2016 Jan 26;155(1):127-32. Epub 2015 Dec 26.

Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10549-015-36
Web Search
http://link.springer.com/10.1007/s10549-015-3656-0
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3656-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947530PMC
January 2016

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.

J Clin Oncol 2015 Jul 26;33(19):2158-65. Epub 2015 May 26.

Diego Tosi, Yassine Laghzali, Marie Vinches, Marie Alexandre, Nadia Hayaoui, Sophie Gourgou, and Caroline Mollevi, Institut Régional du Cancer de Montpellier-Val d'Aurelle, Montpellier, France; Krisztian Homicsko, Centre Hospitalier Universitaire Vaudois, Lausanne; Anna Durigova, Geneva University Hospitals, Geneva, Switzerland; and Angelica Fasolo, Gianluca Del Conte, and Luca Gianni, San Raffaele-Scientific Institute, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1082DOI Listing
July 2015

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

J Clin Oncol 2015 Apr 23;33(10):1136-42. Epub 2015 Feb 23.

Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA; Thomas M. Suter, Bern University Hospital, Bern, Switzerland; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York; Marc L. Citron, Hofstra North Shore-Long Island Jewish School of Medicine, New Hyde Park, NY; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Gilles Romieu, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier; Mario Campone, Institut de Cancérologie de l'Ouest/René Gauducheau, Nantes Saint-Herblain, France; Claudio Zamagni, Policlinico Sant'Orsola-Malpighi Hospital, Bologna; Luca Gianni, San Raffaele Hospital, Milan, Italy; and Na Xu and Melanie Smitt, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.7782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657012PMC
April 2015

Pathological complete response in breast cancer--authors' reply.

Lancet 2015 Jan;385(9963):114-5

German Breast Group, Neu-Isenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)60018-6DOI Listing
January 2015

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.

Invest New Drugs 2014 Dec 6;32(6):1188-96. Epub 2014 Jun 6.

Drug Development Department (DITEP), University Paris Sud, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0119-0DOI Listing
December 2014

Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples.

PLoS One 2014 29;9(1):e86511. Epub 2014 Jan 29.

Department of Molecular Biotechnology and Life Sciences, University of Turin, Turin, Italy ; Center for Translational Genomics and Bioinformatics, Ospedale San Raffaele, Milan, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086511PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906036PMC
September 2014

Hallmarks of triple negative breast cancer emerging at last?

Cell Res 2014 Aug 9;24(8):904-5. Epub 2014 May 9.

Department of Medical Oncology, San Raffaele Hospital, 20132 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cr.2014.61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123289PMC
August 2014

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

J Clin Oncol 2014 Jul 9;32(20):2159-65. Epub 2014 Jun 9.

Evandro de Azambuja and Martine J. Piccart-Genhart, Institut Jules Bordet; Evandro de Azambuja, Breast European Adjuvant Study Team; Martine J. Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Marion J. Procter and Dominique Agbor-Tarh, Frontier Science Scotland, Kincraig, Kingussie; David A. Cameron, University of Edinburgh and Western General Hospital, Edinburgh; Ian E. Smith, Royal Marsden Hospital and the Institute of Cancer Research; Mitch Dowsett, the Royal Marsden National Health Service Trust, London, United Kingdom; Dirk J. van Veldhuisen, University of Groningen, Groningen, the Netherlands; Otto Metzger-Filho and Richard D. Gelber, Dana-Farber Cancer Institute, Boston, MA; Jutta Steinseifer, F. Hoffmann-La Roche, Basel; Thomas M. Suter, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland; Michael Untch, HELIOS Klinikum Berlin, Buch; Christian Jackisch, Klinikum Offenbach, Offenbach, Germany; Luca Gianni, San Raffaele Institute, Milan, Italy; Jose Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Richard Bell, Andrew Love Cancer Centre, Geelong Hospital, Geelong, Australia; and Brian Leyland-Jones, Edith Sanford Breast Cancer Research Institute, Sioux Falls, SD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.9288DOI Listing
July 2014

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authors' reply.

Lancet Oncol 2014 Jul;15(8):e304-5

Ospedale San Raffele Scientific Institute, 20132 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70288-8DOI Listing
July 2014

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

J Clin Oncol 2014 May 14;32(14):1437-44. Epub 2014 Apr 14.

Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Reshma L. Mahtani, Sylvester Comprehensive Cancer Center, Miami, FL; Kathy S. Albain, Loyola University Chicago Stritch School of Medicine, Maywood, IL; Liang Fang, Glenn Michelson, Genentech, South San Francisco, CA; Howard A. Burris, Sarah Cannon Research Institute, Nashville, TN; Véronique Diéras, Institut Curie, Paris; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Nadia Harbeck, Interdisciplinary Breast Cancer, University of Cologne, Cologne; Nadia Harbeck, Breast Cancer University of Munich, Germany; Luca Gianni, San Raffaele Hospital, Milan; Diana Crivellari, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Italy; Sanne L. de Haas, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.6590DOI Listing
May 2014

The immune system and response to HER2-targeted treatment in breast cancer.

Lancet Oncol 2014 Feb;15(2):e58-68

Department of Medical Oncology, Ospedale San Raffaele, 20132 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70477-7DOI Listing
February 2014

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Clin Cancer Res 2014 Jan;20(2):511-21

Authors' Affiliations: Translational Genomics Group, Vall d'Hebron Institute of Oncology; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona; Hospital Clinico Universitario, Valencia, Spain; Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy; Roche, Pharma Research and Early Development, Penzberg; Frauenklinik vom Roten Kreuz, Munich, Germany; University of North Carolina, Chapel Hill, North Carolina; NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation; NN Blokhin Russian Cancer Centre; Central Clinical Hospital named after N A Semashko, Moscow, Russia; and Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0239DOI Listing
January 2014

Anthracycline cardiotoxicity.

Top Curr Chem 2008 ;283:21-44

University Campus Bio-Medico of Rome, CIR and Drug Sciences, Via Alvaro del Portillo 21, 00128, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/128_2007_11DOI Listing
April 2013

HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?

J Natl Cancer Inst 2013 Feb 8;105(3):161-3. Epub 2013 Jan 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs636DOI Listing
February 2013

Surrogate markers for targeted therapy-based treatment activity and efficacy.

J Natl Cancer Inst Monogr 2011 ;2011(43):91-4

Department of Medical Oncology, hSR-San Raffaele, via Olgettina 60, Milano 20132, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgr024DOI Listing
March 2012

Treatment of HER2-positive breast cancer: current status and future perspectives.

Nat Rev Clin Oncol 2011 Nov 29;9(1):16-32. Epub 2011 Nov 29.

Breast Cancer Research Program, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, 1310 24th Avenue South, Nashville, TN 37212-2637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.177DOI Listing
November 2011

Triple-negative breast cancer: an unmet medical need.

Oncologist 2011 ;16 Suppl 1:1-11

Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2011-S1-01DOI Listing
June 2011

Triple-negative breast cancer: disease entity or title of convenience?

Nat Rev Clin Oncol 2010 Dec 28;7(12):683-92. Epub 2010 Sep 28.

University of North Carolina, 170 Manning Drive, Chapel Hill, NC 27599-7305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.154DOI Listing
December 2010

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

J Clin Oncol 2010 Oct 30;28(28):4316-23. Epub 2010 Aug 30.

Department of Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, PO Box 301439, Houston,TX 77230-1439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.27.2419DOI Listing
October 2010

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

J Clin Oncol 2010 Oct 20;28(30):4554-61. Epub 2010 Sep 20.

Montabone Unit for New Drug Development, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto dei Tumori di Milano, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.27.5867DOI Listing
October 2010

Cardiac deatH prevention by aUtomated defibrillatoRs in ChurcHes: rationale and design of the CHURCH trial.

Am Heart J 2010 Feb;159(2):170-5

Fondazione Don Carlo Gnocchi, Cardiologia Riabilitativa, IRCCS Santa Maria Nascente, Via Capecelatro 66, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2009.11.006DOI Listing
February 2010

An interview with Luca Gianni.

Authors:
Luca Gianni

Lancet 2010 Jan;375(9712):367

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(10)60155-9DOI Listing
January 2010

Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.

Authors:
Luca Gianni

Breast Cancer Res Treat 2009 Oct 23;117(3):599-601. Epub 2009 Apr 23.

Medical Oncology 1, Istituto dei Tumori di Milano, Via Venezian 1, 20133 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-009-0402-5DOI Listing
October 2009

Role of anthracyclines in the treatment of early breast cancer.

J Clin Oncol 2009 Oct 17;27(28):4798-808. Epub 2009 Aug 17.

Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.4791DOI Listing
October 2009

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.

Anticancer Drugs 2009 Aug;20(7):616-24

Fondazione IRCCS Istituto Tumori di Milano, Via Venezian, 1, 20133 Milan, Italy.

View Article

Download full-text PDF

Source
August 2009

Anthracyclines and early breast cancer: the end of an era?

J Clin Oncol 2009 Mar 9;27(8):1155-7. Epub 2009 Feb 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.20.1640DOI Listing
March 2009

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.

Nat Clin Pract Oncol 2009 Feb 23;6(2):93-104. Epub 2008 Dec 23.

Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/ncponc1298
Publisher Site
http://dx.doi.org/10.1038/ncponc1298DOI Listing
February 2009

Anthracycline cardiotoxicity: from bench to bedside.

J Clin Oncol 2008 Aug;26(22):3777-84

Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2007.14.9401
Publisher Site
http://dx.doi.org/10.1200/JCO.2007.14.9401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018290PMC
August 2008

The "other" signaling of trastuzumab: antibodies are immunocompetent drugs.

Authors:
Luca Gianni

J Clin Oncol 2008 Apr 17;26(11):1778-80. Epub 2008 Mar 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.7404DOI Listing
April 2008

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

J Clin Oncol 2008 Feb;26(5):814-9

Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3-200, Seattle, WA 98109-1023, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.3510DOI Listing
February 2008

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.

Cardiovasc Toxicol 2007 ;7(2):67-71

Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, ViaVenezian 1, Milan 20133, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12012-007-0013-5DOI Listing
October 2007

Ixabepilone and the narrow path to developing new cytotoxic drugs.

Authors:
Luca Gianni

J Clin Oncol 2007 Aug 2;25(23):3389-91. Epub 2007 Jul 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.10.9504DOI Listing
August 2007

Targeting TRAIL agonistic receptors for cancer therapy.

Clin Cancer Res 2007 Apr;13(8):2313-7

Cristina Gandini Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-06-2774DOI Listing
April 2007

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.

J Pharmacol Exp Ther 2007 Feb 29;320(2):790-800. Epub 2006 Nov 29.

Department of Drug Sciences and Center of Excellence on Aging, G. d'Annunzio University School of Medicine, Via dei Vestini, 66013 Chieti, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.106.116160DOI Listing
February 2007

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.

J Pharmacol Exp Ther 2006 Jul 13;318(1):424-33. Epub 2006 Apr 13.

Department of Drug Sciences and Center of Excellence on Aging, G. d'Annunzio University School of Medicine, Via dei Vestini, 66013 Chieti, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.106.103846DOI Listing
July 2006

The cost of life: should it matter to doctors?

Authors:
Luca Gianni

Ann Oncol 2006 Mar;17(3):357-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdl036DOI Listing
March 2006

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

Eur J Cancer 2006 Jan 6;42(2):171-8. Epub 2006 Jan 6.

Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500 Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2005.09.033DOI Listing
January 2006

Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer.

Nat Clin Pract Oncol 2004 Nov;1(1):44-50

Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc0025DOI Listing
November 2004